SEARCH

SEARCH BY CITATION

References

  • Amit, I., Citri, A., Shay, T. et al. (2007). A module of negative feedback regulators defines growth factor signaling. Nat. Genet. 39, 503512.
  • Balch, C.M., Buzaid, A.C., Soong, S.J. et al. (2001). Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19, 36353648.
  • Bermudez, O., Pages, G., and Gimond, C. (2010). The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am. J. Physiol. Cell Physiol. 299, C189C202.
  • Bermudez, O., Jouandin, P., Rottier, J., Bourcier, C., Pages, G., and Gimond, C. (2011). Post-transcriptional regulation of the DUSP6/MKP-3 phosphatase by MEK/ERK signaling and hypoxia. J. Cell. Physiol. 226, 276284.
  • Bloethner, S., Chen, B., Hemminki, K., Muller-Berghaus, J., Ugurel, S., Schadendorf, D., and Kumar, R. (2005). Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 26, 12241232.
  • Brose, M.S., Volpe, P., Feldman, M. et al. (2002). BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62, 69977000.
  • Brown, E.R., Doig, T., Anderson, N., Brenn, T., Doherty, V., Xu, Y., Bartlett, J.M.S., Smyth, J.F., and Melton, D.W. (2011). Association of galectin-3 expression with melanoma progression and prognosis. European J. Cancer. doi:10.1016/j.ejca.2011.09.003.
  • Carr, J., and Mackie, R.M. (1994). Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br. J. Dermatol. 131, 7277.
  • Chan, D.W., Liu, V.W., Tsao, G.S., Yao, K.M., Furukawa, T., Chan, K.K., and Ngan, H.Y. (2008). Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 29, 17421750.
  • Cheng, S.L., Huang-Liu, R., Sheu, J.N., Chen, S.T., Sinchaikul, S., and Tsay, G.J. (2007). Toxicogenomics of A375 human malignant melanoma cells. Pharmacogenomics 8, 10171036.
  • Cohen, C., Zavala-Pompa, A., Sequeira, J.H., Shoji, M., Sexton, D.G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N., and Arbiser, J.L. (2002). Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res. 8, 37283733.
  • Cully, M., You, H., Levine, A.J., and Mak, T.W. (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184192.
  • Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 43404346.
  • Dahl, C., and Guldberg, P. (2007). The genome and epigenome of malignant melanoma. Apmis 115, 11611176.
  • Furukawa, T., Sunamura, M., Motoi, F., Matsuno, S., and Horii, A. (2003). Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am. J. Pathol. 162, 18071815.
  • Furukawa, T., Tanji, E., Xu, S., and Horii, A. (2008). Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells. Biochem. Biophys. Res. Commun. 377, 317320.
  • Goel, V.K., Lazar, A.J., Warneke, C.L., Redston, M.S., and Haluska, F.G. (2006). Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. 126, 154160.
  • Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A.N., Busam, K., and Polsky, D. (2003). Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 63, 39553957.
  • Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., and Mills, G.B. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 9881004.
  • Jat, P.S., Cepko, C.L., Mulligan, R.C., and Sharp, P.A. (1986). Recombinant retroviruses encoding simian virus 40 large T antigen and polyomavirus large and middle T antigens. Mol. Cell. Biol. 6, 12041217.
  • Jovanovic, B., Krockel, D, Linden, D., Nilsson, B., Egyhazi, S., and Hansson, J. (2008). Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J. Invest. Dermatol. 128, 26962704.
  • Larue, L., Dougherty, N., Bradl, M., and Mintz, B. (1993). Melanocyte culture lines from Tyr-SV40E transgenic mice: models for the molecular genetic evolution of malignant melanoma. Oncogene 8, 523531.
  • Li, W., and Melton, D.W. (2011). Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene. doi: 10.1038/onc.2011.426.
  • Mansour, S.J., Matten, W.T., Hermann, A.S., Candia, J.M., Rong, S., Fukasawa, K., Vane Woude, G.F., and Ahn, N.G. (1994). Transformation of mammalian cells by constitutively active MAP kinase. Science 265, 966970.
  • Meier, F., Schittek, B., Busch, S., Garbe, C., Smalley, K., Satyamoorthy, K., Li, G., and Merlyn, M. (2005). The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci. 10, 29863001.
  • Okudela, K., Yazawa, T., Woo, T. et al. (2009). Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am. J. Pathol. 175, 867881.
  • Palmieri, G., Capone, M., Ascierto, M.L., Gentilcore, G., Stroncek, D.F., Casula, M., Sini, M.C., Palla, M., Mozzillo, N., and Ascierto, P.A. (2009). Main roads to melanoma. J. Transl. Med. 7, 86.
  • Patterson, K.I., Brummer, T., O’Brien, P.M., and Daly, R.J. (2009). Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem. J. 418, 475489.
  • Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B., and Rosen, N. (2009). (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl Acad. Sci. USA 106, 45194524.
  • Ryu, B., Kim, D.S., Deluca, A.M., and Alani, R.M. (2007). Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One 2, e594.
  • Seger, R., Ahn, N.G., Posada, J., Munar, E.S., Jensen, A.M., Cooper, J.A., Cobb, M.H., and Krebs, E.G. (1992). Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J. Biol. Chem. 267, 1437314381.
  • Selfridge, J., Song, L., Brownstein, D.G., and Melton, D.W. (2010). Mice with DNA repair gene Ercc1 deficiency in a neural crest lineage are a model for late-onset Hirschsprung disease. DNA Repair 9, 653660.
  • Serrels, B., Sandilands, E., Serrels, A., Baillie, G., Houslay, M.D., Brunton, V.G., Canel, M., Machesky, L.M., Anderson, K.I., and Frame, M.C. (2010). A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity. Curr. Biol. 20, 10861092.
  • Shields, J.M., Thomas, N.E., Cregger, M. et al. (2007). Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res. 67, 15021512.
  • Smalley, K.S. (2003). A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int. J. Cancer 104, 527532.
  • Smalley, K.S., Haass, N.K., Brafford, P.A., Lioni, M., Flaherty, K.T., and Herlyn, M. (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5, 11361144.
  • Smalley, K.S., Contractor, R., Nguyen, T.K. et al. (2008). Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res. 68, 57435752.
  • Song, L., Ritchie, A.-M., McNeil, E.M., Li, W., and Melton, D.W. (2011). Identification of DNA repair gene Ercc1 as a novel target in melanoma. Pigment Cell Melanoma Res. 24, 966971.
  • Uribe, P., Andrade, L., and Gonzalez, S. (2006). Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J. Invest. Dermatol. 126, 161166.
  • Xu, S., Furukawa, T., Kanai, N., Sunamura, M., and Horii, A. (2005). Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J. Hum. Genet. 50, 159167.
  • Zepter, K., Haffner, A.C., Trefzer, U., and Elmets, C.A. (1995). Reduced growth factor requirements and accelerated cell-cycle kinetics in adult human melanocytes transformed with SV40 large T antigen. J. Invest. Dermatol. 104, 755762.
  • Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Palmer, A.A., Zhang, X.D., Thompson, J.F., Bron, L.P., and Hersey, P. (2005). Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J. Clin. Pathol. 58, 11631169.
  • Zimmermann, S., and Moelling, K. (1999). Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286, 17411744.